Stryker Co. (NYSE:SYK) Shares Sold by CHICAGO TRUST Co NA

CHICAGO TRUST Co NA reduced its position in Stryker Co. (NYSE:SYK) by 3.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,560 shares of the medical technology company’s stock after selling 255 shares during the period. CHICAGO TRUST Co NA’s holdings in Stryker were worth $2,722,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. Brookstone Capital Management raised its holdings in shares of Stryker by 29.6% during the 4th quarter. Brookstone Capital Management now owns 3,094 shares of the medical technology company’s stock valued at $1,114,000 after buying an additional 706 shares during the period. Trust Co. of Toledo NA OH raised its holdings in shares of Stryker by 3.6% during the 4th quarter. Trust Co. of Toledo NA OH now owns 1,630 shares of the medical technology company’s stock valued at $587,000 after buying an additional 56 shares during the period. Fiduciary Alliance LLC purchased a new stake in shares of Stryker during the 4th quarter valued at about $2,486,000. Clark & Stuart Inc purchased a new stake in Stryker during the 4th quarter worth approximately $5,348,000. Finally, Czech National Bank increased its holdings in Stryker by 6.6% during the 4th quarter. Czech National Bank now owns 74,430 shares of the medical technology company’s stock worth $26,799,000 after purchasing an additional 4,587 shares during the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Stryker Stock Performance

Shares of SYK stock traded down $3.28 during trading on Monday, reaching $362.38. The company had a trading volume of 410,567 shares, compared to its average volume of 1,153,375. The company has a market capitalization of $138.15 billion, a PE ratio of 38.84, a PEG ratio of 2.82 and a beta of 0.95. The firm’s 50 day simple moving average is $375.40 and its two-hundred day simple moving average is $357.95. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22. Stryker Co. has a one year low of $307.23 and a one year high of $398.20.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The company had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. During the same quarter last year, the firm earned $2.46 EPS. Stryker’s revenue for the quarter was up 11.9% compared to the same quarter last year. Sell-side analysts forecast that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be given a $0.84 dividend. This is an increase from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 annualized dividend and a yield of 0.93%. Stryker’s payout ratio is presently 36.01%.

Insider Transactions at Stryker

In related news, CEO Kevin Lobo sold 57,313 shares of Stryker stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares of the company’s stock, valued at $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 5.90% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on SYK shares. Robert W. Baird lifted their price objective on Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Royal Bank of Canada reiterated an “outperform” rating and issued a $425.00 price target on shares of Stryker in a report on Tuesday, January 7th. Evercore ISI boosted their price target on Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a report on Wednesday, October 30th. Canaccord Genuity Group boosted their price target on Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Finally, Barclays boosted their price target on Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a report on Thursday, October 31st. Four analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $405.80.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.